跳转至内容
Merck
所有图片(1)

Key Documents

View All Documentation

N7662

Sigma-Aldrich

Nafarelin acetate salt hydrate

≥95% (HPLC), solid

别名:

5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-3-(2-naphthyl)-D-alanyl-L-leucyl-L-arginyl-L-prolylglycinamide acetate salt hydrate

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C66H83N17O13 · xC2H4O2 · yH2O
CAS号:
86220-42-0
分子量:
1322.47 (anhydrous free base basis)
MDL號碼:
MFCD00895733
分類程式碼代碼:
12352200
PubChem物質ID:
329818673
NACRES:
NA.77

化驗

≥95% (HPLC)

形狀

solid

顏色

white

溶解度

H2O: >5 mg/mL

儲存溫度

2-8°C

SMILES 字串

O.CC(O)=O.CC(C)C[C@H](NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H](Cc4c[nH]c5ccccc45)NC(=O)[C@H](Cc6cnc[nH]6)NC(=O)[C@@H]7CCC(=O)N7)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N8CCC[C@H]8C(=O)NCC(N)=O

InChI

1S/C66H83N17O13.C2H4O2.H2O/c1-36(2)25-48(58(89)76-47(13-7-23-71-66(68)69)65(96)83-24-8-14-54(83)64(95)73-33-55(67)86)77-60(91)50(28-38-15-18-39-9-3-4-10-40(39)26-38)78-59(90)49(27-37-16-19-43(85)20-17-37)79-63(94)53(34-84)82-61(92)51(29-41-31-72-45-12-6-5-11-44(41)45)80-62(93)52(30-42-32-70-35-74-42)81-57(88)46-21-22-56(87)75-46;1-2(3)4;/h3-6,9-12,15-20,26,31-32,35-36,46-54,72,84-85H,7-8,13-14,21-25,27-30,33-34H2,1-2H3,(H2,67,86)(H,70,74)(H,73,95)(H,75,87)(H,76,89)(H,77,91)(H,78,90)(H,79,94)(H,80,93)(H,81,88)(H,82,92)(H4,68,69,71);1H3,(H,3,4);1H2/t46-,47-,48-,49-,50+,51-,52-,53-,54-;;/m0../s1

InChI 密鑰

FSBTYDWUUWLHBD-UDXTWCDOSA-N

生化／生理作用

Nafarelin acetate salt hydrate is a gonadotrophin releasing hormone analogue and luteinizing hormone releasing hormone (LH-RH) agonist.

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

S Goericke-Pesch et al.
Theriogenology, 73(7), 920-926 (2010-01-26)
Efficacy of a slow-release gonadotropin-releasing hormone (GnRH)-agonist implant (Gonazon) was assessed in 53 male dogs presented with benign prostatic hyperplasia (BPH), hypersexuality, aggressive behavior (either alone or in combination), excessive micturition, or to suppress fertility. Changes in testosterone (T) and
Frances R Batzer
Journal of minimally invasive gynecology, 13(6), 539-545 (2006-11-14)
While none of the currently available treatment options for endometriosis pain resolved the underlying disease process, there are growing numbers of medical alternatives available. Medical options include the GnRH agonists and antagonists. Review of these treatments in the management of
Rafael F Valle et al.
Annals of the New York Academy of Sciences, 997, 229-239 (2003-12-03)
Endometriosis is often a perplexing medical condition for both the physician and the patient. Accordingly, development of treatment strategies based on the needs of the individual patient is highly desirable. Although endometriosis has been part of the clinical practice for
I Leonard Bernstein et al.
Journal of women's health (2002), 20(4), 643-648 (2011-03-23)
Women have exhibited anaphylaxis, urticaria/angioedema, and autoimmune progesterone dermatitis (APD) coinciding with the progesterone premenstrual rise. We report a detailed immunological evaluation of such a woman responsive to a gonadotropin hormone-releasing agonist (GHRA). Skin testing, enzyme-linked immunosorbent assays (ELISAs), leukocyte
[In vitro fertilization and embryo transfer].
Hidekazu Saito et al.
Nihon rinsho. Japanese journal of clinical medicine, 64 Suppl 4, 80-84 (2006-05-13)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门